Drugs / M1095
Trials 11 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02156466 | Aug 2014 → Aug 2015 | psoriasis | Merck KGaA, Darmstadt, Germany | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT05640245 | Dec 2022 → Sep 2023 | psoriatic arthritis | MoonLake Immunotherapeutics AG | Completed | No outcome recorded |
| Phase 2 | NCT05322473 | Apr 2022 → May 2023 | hidradenitis suppurativa | MoonLake Immunotherapeutics AG | Completed | No outcome recorded |
| Phase 2 | NCT03384745 | Jul 2018 → Jun 2019 | psoriasis | Bond Avillion 2 Development LP | Completed | No outcome recorded |
| Phase 37 trials | ||||||
| Phase 3 | NCT07223138 | Nov 2025 → Feb 2028 expected | psoriatic arthritis | MoonLake Immunotherapeutics AG | Enrolling by invitation | No outcome recorded |
| Phase 3 | NCT07007637 | Jun 2025 → Jun 2028 expected | hidradenitis suppurativa | MoonLake Immunotherapeutics AG | Enrolling by invitation | No outcome recorded |
| Phase 3 | NCT06768671 | Dec 2024 → Sep 2026 expected | hidradenitis suppurativa | MoonLake Immunotherapeutics AG | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06641089 | Oct 2024 → Jan 2027 expected | psoriatic arthritis | MoonLake Immunotherapeutics AG | Recruiting | No outcome recorded |
| Phase 3 | NCT06641076 | Oct 2024 → Feb 2027 expected | psoriatic arthritis | MoonLake Immunotherapeutics AG | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06411899 | May 2024 → Sep 2025 | hidradenitis suppurativa | MoonLake Immunotherapeutics AG | Completed | No outcome recorded |
| Phase 3 | NCT06411379 | May 2024 → Aug 2025 | hidradenitis suppurativa | MoonLake Immunotherapeutics AG | Completed | No outcome recorded |
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 13 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | M1095 | “Sonelokimab (M1095)” NCT05322473 ↗ |
| Known as | ALX-0761 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4298023 ↗ |
| Known as | MSB0010841 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02156466 ↗ |
| Known as | SLK | “trial of sonelokimab (SLK), a nanobody that binds with a similarly high affinity to IL-17A and IL-17F, inhibiting all dimers.” PMID 41053449 ↗ Oct 2025 |
| Known as | Sonelokimab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06768671 ↗ |
| Action | Inhibit | “Interleukin-17F inhibitor” CHEMBL4298023 ↗ |
| Modality | Protein / enzyme biologic | “MSB0010841(Anti- IL-17A/F Nanobody)” NCT02156466 ↗ |
| Route | Subcutaneous | “as SC injection” NCT02156466 ↗ |
| Target | IL17A | “Interleukin 17A inhibitor” CHEMBL4298023 ↗ |
| Target | IL17F | “Interleukin-17F inhibitor” CHEMBL4298023 ↗ |